REFERENCES
  1. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis.Diabet Med 2009; 26: 142–148.
  2. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:2751-3.
  3. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. AmJ Prev Med 2006; 30: 74-7.
  4. Ittaman SV, VanWormer JJ, Rezkalla SH. The role of Aspirin in the prevention of cardiovascular disease. Clin Med Res.2014; 12: 147-54.
  5. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale.Ann Intern Med 2002; 136:157–60.
  6. Colwell JA, American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2003; 26:S87–S88.
  7. Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose Aspirin in the primary prevention of cardiovascular disease in women.N Engl J Med 2005; 352: 1293–304.
  8. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–35.
  9. The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose Aspirin in the primary prevention of ischaemic heart disease in men at increased risk.Lancet 1998; 351: 233–41.
  10. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose Aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
  11. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55: 2878–2886.
  12. Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med. 2017;34(3):316–27.
  13. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992; 268: 1292–1300.
  14. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo-controlled trial of Aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
  15. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.JAMA 2008; 300: 2134–2141.
  16. Sasso F C, Marfella R • Pagano A, Porta G, Signoriello G et al. Lack of effect of Aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study. Acta Diabetol. 2014
  17. Group ASC, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of Aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.
  18. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study.Circulation . 2007; 115 (12):1544-1550.
  19. Tierney, Fennessy F,Hayes DB.ABC of arterial and vascular disease: secondary prevention of peripheral vascular disease. BMJ 2000;320:1262-5.
  20. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al. Critical issues in peripheral arterial disease detection and management. A call to action. Arch Intern Med 2003;163:884-92.
  21. Scottish Intercollegiate Guidelines Network. Diagnosis and management of peripheral arterial disease: a national clinical guideline. 2006. No 89. www.sign.ac.uk/pdf/sign89.pdf.
  22. Norgren L, Hiatt WR, Dormandy J, Mehler MR,Harris KH, Fowkes FGR, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg.2007;33(suppl 1):S1-75.
  23. Yoshihiko Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. 10-Year Follow-Up of a Randomized Controlled Trial. Circulation. 2017;135:659–670.
  24. Whiting PF, Rutjes AW, Westwood ME, et al; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536